Opinion

Video

Common Adverse Reactions to EGFR Therapy

Alan Chin, PharmD, BCOP, presents an overview of the most prevalent and common adverse reactions associated with EGFR-targeted therapies in metastatic NSCLC and shares strategies to mitigate toxicities, with a focus on managing dermatologic events such as rash and itching.

  1. Provide a broad overview of common adverse effects associated with EGFR-targeted therapies in metastatic NSCLC.
  2. What proactive strategies do you recommend for preventing dermatologic toxicities, such as rash and acneiform eruptions, in patients receiving EGFR-targeted therapies?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
1 KOL is featured in this series.
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
5 experts in this video
1 expert is featured in this series.
5 experts in this video
5 experts in this video
Related Content
ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC
June 30th 2025

ASCO 2025: Using Discrete Choice Data to Support Personalized Pharmacy Counseling in ALK+ NSCLC

Christopher Danes, PhD Alana Hippensteele, Lead Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

3D rendering of lung cancer screening x-ray | Image Credit: © Vector Market- stock.adobe.com
Published: June 23rd 2025 | Updated: June 23rd 2025

FDA Approves Datopotamab for Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment
June 27th 2024

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

OPC 2025: Advancing Precision Oncology Through Pharmacy-Led Innovation
June 19th 2025

OPC 2025: Advancing Precision Oncology Through Pharmacy-Led Innovation

Alana Hippensteele, Lead Editor
Visualization of human lungs with cancer | Image Credit: © iDoPixBox - stock.adobe.com
June 19th 2025

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Alexandra Gerlach, Associate Editor